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Background:  
Group B Streptococcus (GBS) is a leading cause of serious infection in young 
infants. We aimed to define the current burden and clinical features of 
invasive GBS disease in infants younger than 90 days in the UK and the 
Republic of Ireland (ROI), together with the characteristics of disease-causing 
isolates.  
 
Methods: 
Prospective, active national surveillance was undertaken from April 2014 to 
May 2015 through the British Paediatric Surveillance Unit (BPSU), 
microbiology reference laboratories and national public health agencies. 
Results were compared with those obtained from surveillance undertaken 
using the same methodology in 2000-2001. Isolates were characterised by 
serotyping, multi-locus sequence typing, and antimicrobial susceptibility 
testing.  
 
Findings:  
Eight hundred and fifty-six cases were identified, an incidence rate of 
0·94/1000 live-births. Early onset disease (EOD) represented 60% of cases 
(0·57/1000) and was higher than in 2000-2001 (0·48/1000). The incidence of 
late onset disease (LOD) was also higher (0·37/1000  vs. 0·24/1000). The 
overall case fatality rate (CFR) was 6·2% (n=53), a decline since 2000-2001 
(9·7%), reflecting a reduction in EOD CFR (10·6% to 5·2%) but not LOD CFR 
(8·0% to 7·7%).  
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The predominant serotypes were III (n=258, 60%) and Ia (n=73, 17%); five 
serotypes (Ia, Ib, II, III, V) comprised 94% (n=377) of serotyped isolates 
(n=402). 
 
Interpretation: 
The incidence of invasive infant GBS disease in the UK and Ireland has 
increased since 2000-2001. The burden of EOD incidence has not declined 
despite the introduction of national prevention guidelines. New strategies for 
prevention are required.   
 
Funding: 
Meningitis Now  
 
 
 
 
 
 
 
 
 
 
 
 
 
 5 
Introduction  
Streptococcus agalactiae (group B Streptococcus, GBS) is an important 
cause of disease in neonates and young infants. It is the most common cause 
of serious bacterial infections (septicaemia, pneumonia) in the first week of life 
and of meningitis in the first three months of life.1-2 GBS meningitis is 
associated with significant long-term neurodisability.3  In a recent systematic 
review and meta-analysis, the mean case fatality ratio for invasive GBS 
disease in infants was 9·6%, three times higher in low-income countries 
(12·6%) than in high-income countries (4·6%).4   
 
GBS colonises the gastrointestinal and genital tracts of around 20% of 
pregnant women.5 Transmission from colonised mothers to their infants can 
occur prior to or during birth, and this may result in early onset disease (in the 
first 6 days of life, EOD). Late onset disease (LOD) (7-89 days of age) can 
also result from vertical transmission but also from nosocomial or community 
transmission. Intravenous antibiotics given to the mother during labour may 
prevent EOD and intrapartum antibiotic prophylaxis (IAP) strategies have 
been adopted in many countries.6–8 Such strategies are based either on 
identifying at-risk women using swab-based screening or on the presence of 
clinical risk factors.9 IAP-based strategies, however, do not prevent LOD.  
 
In 2000-2001, we conducted the first enhanced national surveillance of GBS 
in the UK and Ireland.10 We identified 568 cases (incidence, 0·72/1,000 live-
births) in the first three months of life, including 377 EOD cases (incidence 
0·48/1,000 live-births).  
 
Several initiatives have subsequently been implemented in the UK and Ireland 
which may have had an impact on the burden of disease in young infants. In 
2003, the Royal College of Obstetricians and Gynaecologists (RCOG) 
published risk-based guidelines for the prevention of EO-GBS (updated in 
2012).7 In 2012, the National Institute for Health and Care Excellence (NICE) 
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published guidelines on the prevention and treatment of early onset neonatal 
infection, which extended the risk factor-based approach to include premature 
pre-labour rupture of membranes and premature rupture of membranes >18 
hours.11  
 
Vaccines against GBS are currently undergoing clinical trials in pregnant 
women.12 Knowledge of the current burden of GBS disease and the 
responsible serotypes is critical for evaluating both the success of current 
guidelines as well as the potential impact of a GBS vaccination programme in 
pregnancy. 
 
We undertook an enhanced, prospective, population-based surveillance study 
of GBS in young infants in the UK and ROI. As the same methodology was 
used for the 2000-2001 surveillance, we directly compared results between 
the two time-periods.10 
 
Methods 
Enhanced national surveillance of invasive GBS disease in infants younger 
than 90 days was undertaken between 1st April 2014 and 30th April 2015 
through the British Paediatric Surveillance Unit (BPSU), 13,14 in collaboration 
with microbiology reference laboratories, microbiology laboratory surveillance 
and Public Health agencies in England, Wales, Scotland, Northern Ireland 
(NI), and ROI.  
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BPSU reports were made using the “orange card” system, in which an email 
and/or card was sent on a monthly basis to all consultant paediatricians in the 
British Isles, asking them to notify any case with a positive sterile site culture 
for GBS in an infant younger than three months of age. Laboratory-confirmed 
cases were also identified by interrogation of the Public Health England (PHE) 
national electronic surveillance database routinely used by hospital 
laboratories in England, Wales, and NI. Cases were also identified through 
reference laboratories of PHE, 15 Health Protection Scotland, 16 Public Health 
Agency NI, 17 and the Irish Meningitis and Sepsis Reference Laboratory 
(IMSRL), 18 which receive GBS isolates for confirmation and serotyping. All 
hospital laboratories were encouraged to submit isolates to their respective 
reference laboratories during the surveillance. At the end of the surveillance 
period, all hospital laboratories were individually contacted to confirm the 
completeness of their surveillance.  
 
Finally, cases were ascertained directly from the public health agencies of 
Scotland, NI, and ROI. In ROI and NI invasive GBS disease has been a 
notifiable condition since 2012 and 2013 respectively. 
 
Serotyping and multi-locus sequence typing (MLST) of GBS isolates was 
performed by PHE and IMSRL. Briefly, isolates were cultured onto Columbia 
agar plates supplemented with horse blood (Oxoid, Thermo Scientific, UK) 
and incubated aerobically at 37°C for 24 h. Serological classification based on 
capsular polysaccharide types Ia, Ib and II to IX was performed using latex 
agglutination according to the manufacturer’s instructions (Statens Serum 
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Institut, Copenhagen, Denmark). Bacterial cells were re-suspended in a pre-
lysis buffer composed of 2 mg lysozyme (Sigma-Aldrich, UK), 120 U 
mutanolysin (Sigma-Aldrich, UK), 400 µg RNase A (Qiagen, Germany) and 20 
µl proteinase K (>600 mAU/mL) and incubated for 1 h at 37°C, 2 h at 56°C 
followed by 1h at 80°C. DNA was then extracted using the QIAsymphony SP 
system and the QIAsymphony DSP mini kit (Qiagen, Germany) according to 
the manufacturers’ instructions. The sequencing reads were trimmed for 
quality by removing end nucleotides of Phred quality score of less than 30. 
The MLST sequence types of isolates were determined from processed 
sequencing reads using in-house bioinformatics pipelines developed in PHE 
and an external database (http://pubmlst.org/sagalactiae/). 19 
 
To test for antimicrobial susceptibility minimum inhibitory concentrations to 
erythromycin, clindamycin and penicillin were determined at PHE via agar 
dilution. For erythromycin and clindamycin, a 0·06 to 128 µg/mL range of 
antibiotic concentrations were tested and for penicillin a range of 0.015 to 0.5 
µg/mL were tested.  Iso-Sensitest agar containing 5% horse blood (Oxoid, 
Thermo Scientific, UK) was inoculated with 1·5x108 CFU/spot of sample using 
a multipoint inoculator and incubated aerobically overnight at 37°C. British 
Society of Antimicrobial Chemotherapy (BSAC) criteria were used to 
determine whether isolates were resistant or susceptible to erythromycin 
(susceptibility and resistance, ≤0·25 µg/mL and >0·5 µg/mL), clindamycin 
(susceptibility, ≤0·5 µg/mL) and penicillin (susceptibility, ≤0·25 µg/mL). 20 
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Data from all sources were entered into a single Excel database and de-
duplicated at regular intervals. The responsible paediatricians were sent a link 
to a secure web-based electronic questionnaire, or a paper version of the 
same questionnaire, which requested information on demographics, antenatal 
and intrapartum risk factors (in EOD cases), disease presentation and 
management, and outcomes at hospital discharge. Clinical presentation was 
defined as meningitis, if the CSF culture was positive and / or if the 
paediatrician indicated it was treated as meningitis; bacteraemic pneumonia, if 
the blood culture was positive and there were chest x-ray changes compatible 
with pneumonia; focal infection, if the blood culture was positive and there 
were clinical features of a focal infection (typically, septic arthritis or 
osteomyelitis); and septicaemia, if the blood culture was positive and there 
were no clinical features of a focal infection. Poor outcome was defined as 
any major or minor disability identified by the clinician at hospital discharge. 
For cases where antenatal and intrapartum information was not available, with 
the named paediatrician’s permission, we sought the assistance of the UK 
Obstetric Surveillance System (UKOSS) to obtain the information. 21. UKOSS 
has a nominated reporter in each NHS Trust who has access to maternity and 
perinatal data.  
 
Risk factors that were sought in EOD cases were those specified in the 
RCOG guideline for prevention of early-onset GBS disease (maternal fever 
during labour, known maternal GBS carriage, previous baby with invasive 
GBS, GBS bacteriuria, suspected chorioamnionitis), 6 the NICE antibiotics for 
early onset infection guideline (as above plus premature pre-labour rupture of 
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membranes, premature rupture of membranes >18 hours), 11 and the CDC 
Guidelines for the Prevention of Perinatal Group B Streptococcal (GBS) 
Disease (as above plus rupture of membranes ≥ 18 hours and prematurity < 
37 weeks). 9 
 
Data were analysed using Stata version 13·1 (StataCorp, College Station, 
Texas).  Cases were classified as early or late onset and term (≥37 weeks) or 
premature (<37 weeks). Incidence was calculated using live-births in 2014 
(after adjustment for the 13-month surveillance period). Live-births data were 
obtained from the Office for National Statistics (ONS), 22 National Records of 
Scotland, 23 Republic of Ireland Central Statistics Office, 24 and Northern 
Ireland Statistics and Research Agency. 25 Incidence by birth-weight was 
calculated for England and Wales, using ONS data. The binomial method was 
used to calculate 95% confidence intervals (CI). Seven-day and 28-day case 
fatality rates (CFR) based on the date of diagnosis were calculated.  
 
Continuous data that were non-normally distributed were described as median 
with interquartile ranges (IQRs).  
 
The study was approved by the South East Coast – Brighton and Sussex 
Research Ethics Committee (REC Reference: 13/LO/19112).  The public 
health agencies in the UK and Ireland have legal permission to collect 
laboratory data for infectious disease surveillance and control.  
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Role of the funding source.  
The funders of the study had no role in study design, data collection, data 
analysis, data interpretation, or writing of the report. The corresponding author 
had full access to all the data in the study and had final responsibility for the 
decision to submit for publication. 
 
Results 
There were 856 cases of invasive GBS in infants <3 months of age over the 
13-month surveillance period (54·2% male). Information from both 
paediatricians and microbiology laboratories was available for 657 (76·8%) 
infants, from microbiology laboratories alone for 142 (16·6%) and from 
paediatricians alone for 59 (6·9%). Forty-one cases were from twin 
pregnancies, including six infant pairs.  
 
Positive GBS cultures were obtained from blood in 90% (n=769) of cases, 
CSF in 9·5% (n=81; CSF alone in 28 [3·3%] cases, CSF and blood in 53 
[6·2%] cases) and from joint fluid and blood (n=2) in <1%.  
 
Age at presentation: 
More than half the cases (n=517, 60·4%) presented at 0-6 days (EOD), 
39·5% presented at 7-89 days (n=339, LOD); 193 (56·9%) of LOD cases 
presented at 7-28 days and 130 (38·3%) at 29-89 days (specific day not 
reported for 16 LOD cases) (Supplementary Figure 1). The median age at 
presentation for LOD disease was 23 days (IQR 15-38); infants born at term 
presented at a median age of 20 days (IQR 14-30) and those born 
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prematurely (<37 weeks gestation, representing 38·8% (n=107) of LOD 
cases), presented at 35 days (IQR 21-55). 
 
Incidence: 
The GBS incidence in <90 day-old infants was 0·94/1,000 live-births; EOD 
incidence 0·57/ 1,000 live births and LOD incidence 0·37/ 1,000 live-births 
(Table 1). The incidence was similar across the five countries; the lowest 
incidence was in the Republic of Ireland. When categorized by birth-weight, 
babies born at <1500g had the highest incidence, approximately 14-fold 
higher than that of babies >2500g (Table 2, Supplementary Table 1). A similar 
trend was observed for gestational age (Supplementary Table 2).  
 
Clinical presentation: 
The most common clinical syndrome was septicaemia (n=449, 52·5%), 
followed by meningitis (n=155, 18·1%), bacteraemic pneumonia (n=107, 
12·5%) and focal infections (n=6, 0·7%). A lumbar puncture was performed in 
86% (n=600) of cases; of the remaining 14%, either the procedure was 
unsuccessful or the baby deemed too ill for lumbar puncture. Infants with LOD 
were more likely to present with meningitis than those with EOD (98 [28·9%] 
vs. 57 [11%]). The overall meningitis incidence was 0·17 per 1,000 live births. 
 
Risk factors: 
Overall, 22·2% (n=94) of EOD cases and 38·8% (n=107) of LOD cases were 
born prematurely and 14·6% (n=62) of EOD cases were born at <35 weeks 
gestation (Table 3). Notably, 19% (n=55) of LOD cases were on a neonatal 
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unit at the time of onset and 95% of these babies had been born prematurely. 
Of the LOD cases presenting from home, 24% were born prematurely. The 
median gestational age of LOD babies who were resident on neonatal units at 
the time of presentation was 28 weeks and their median age at disease onset 
was 34 days.  
 
Among 517 EOD cases, 429 (83%) had available clinical information. Of 
these, 152 (35·4%) had ≥1 RCOG risk factor reported (Table 3); 44% of those 
with risk factors had received IAP at a median time of 2 hours before delivery 
(IQR 1-4 hours). For risk factors based on NICE and CDC guidelines, the 
corresponding figures were 41·3% (n=177) and 59% (n=253).  
 
Isolates: 
Isolates were received from 402 (47%) cases. The only significant difference 
between cases with and without submitted isolates was a higher prevalence 
of meningitis (22% vs. 14%). The predominant serotypes were III (n=258, 
60%) and Ia (n=73, 17%); five serotypes (Ia, Ib, II, III, V) comprised 94% of all 
isolates (Figure 1, supplementary Table 3). The proportion of serotype III and 
Ia isolates differed between EOD and LOD cases; 50·7% (n=116) of EOD 
isolates were serotype III and 20·1% (n=46) were Ia, compared with 72·3% 
(n=125) and 13·3% (n=23) of LOD isolates respectively. The proportion of 
serotype III isolates also differed according to disease presentation 
comprising 78% (n=45) of meningitis isolates, 53% (n=107) of sepsis isolates 
and 47% (n=25) of bacteraemic pneumonia isolates.  
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MLST analysis revealed 57 sequence types (ST) (Supplementary Table 4). 
Twenty-one of the STs were novel, of which seven were single locus variants 
of ST17. The prevalent STs were ST17 (n=185, 43%) and ST23 (n=55, 13%). 
The majority of serotype III (n=197, 76%) and Ia isolates (n=55, 75%) 
belonged to ST17 and ST23 respectively. The majority of meningitis cases 
were attributable to serotype III / ST17 isolates (n=56, 62%), of these 32·7% 
(n=18) were attributed to EOD and 67·3% (n=37) to LOD. A greater diversity 
of STs were identified amongst isolates from EOD (48 STs) than LOD (30 
STs) and the majority (≥91%) of ST12 and ST28 isolates were associated 
with EOD cases. 
 
None of the isolates were resistant to penicillin while resistance to clindamycin 
and erythromycin was identified in 17% (n=72) and 24% (n=101) of isolates 
respectively. Of the 31 isolates which were resistant to erythromycin but 
sensitive to clindamycin 15 (48·4%) showed inducible clindamycin resistance. 
A large proportion of serotype II (n=6, 33%) and V (n=12, 43%) isolates were 
resistant to erythromycin and clindamycin. Sixteen percent (n=70) of isolates 
were resistant to both clindamycin and erythromycin. Only 6% (n=28) of 
isolates were susceptible to tetracycline; 91% (n=389) were fully resistant 
while 3% (n=12) had intermediate resistance.  
 
Outcomes: 
There were 53 deaths (CFR, 6·2%), 41 died within seven days of disease 
onset (7-day CFR; 4·9%). 21% of the deaths were in infants with meningitis; 
3/57 [5·3%] with EOD meningitis and 8/98 [8·2%] with LOD meningitis. Half 
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the deaths were in premature infants. The highest CFR was in very preterm 
infants (≤33 weeks gestation) with EOD (12/45 cases, 27%), 10-fold higher 
than that of infants born at term (9/330 cases, 2.7%) (Table 4). Among the 27 
EOD deaths, 37% (n=10) had ≥1 RCOG risk factors and only one had 
received IAP.  
 
Of the infants who survived and whose discharge status was known (n=631), 
90·6% were clinically well, including 92·6% of EOD and 87·6% of LOD cases.  
 
 16 
Discussion 
 
Our study defines the current burden of invasive GBS disease in infants aged 
<90 days in the UK and Republic of Ireland. It provides information on the risk 
factors and the changes in disease incidence since the previous national 
surveillance 15 years ago.10 We have defined the on-going burden of GBS in 
a highly vulnerable age group despite national initiatives for prevention, with 
increased incidence of both EO and LO disease across all five countries of 
the British Isles.  
  
Approximately 18% of all GBS cases (30% of LOD cases) presented with 
meningitis, a condition associated with poor outcomes as well as long-term 
neurodevelopmental impairment among survivors.26 The incidence of GBS 
meningitis in 2014-2015 (0·17/1000) is similar to that found in our national 
meningitis surveillance study conducted in 2010-2011 (0·16/1000) and in the 
previous GBS surveillance in 2000-2001 (0·15/1000).27, 10 The burden of GBS 
meningitis in young infants, therefore, has not changed over the last 15 years.   
 
The relative increase in EOD incidence between the two surveillance periods 
(0.57/1000 vs. 0.48/1000, 1.2-fold) is lower than the relative increase in LOD 
incidence (0.37/1000 vs. 0.24/1000, 1.5-fold). One hypothesis for this 
observation could be an increased use of IAP between the two surveillance 
periods, as a result of implementation of national guidelines 6, as this will 
reduce the relative contribution of EOD to the overall burden.  
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The CFR was lower than that recorded in 2000-2001 (6·2% vs. 9·7%), 
primarily among EOD cases (10·6% vs. 5·3%) but not LOD cases (8·2% 
vs.7·7%). It is possible that this reflects the implementation of new guidelines 
for the management of early onset infection in 2012 which promote earlier and 
more appropriate use of antibiotics and supportive care.6  
 
It is difficult to compare risk factors for GBS between the two surveillance 
studies because not all risk factor data were collected in the first period. We 
did, however, observe a lower proportion of cases with two of the three risk 
factors collected in both studies, especially prematurity. Notably, the EOD 
incidence in infants of low birth weight (<2.5kg) in 2014-15 was nearly half 
that observed in 2000-01. It is possible, therefore, that clinicians have 
particularly targeted IAP efforts towards women in preterm labour, and may 
also reflect the introduction of the new guidelines the for the management of 
early onset infection in 2012 which added pre-labour or prolonged rupture of 
membranes in premature labour as risk factors for the receipt of IAP.11 
 
Despite this tentative evidence of an impact of national guidelines on 
subgroups of infants, it is clear that overall the burden of GBS in young infants 
in the UK and Ireland has not declined. The current guidelines target only 
EOD cases, identified by the presence of risk factors, yet we have shown that 
one half to two-thirds of EOD cases do not have such risk factors and are, 
therefore, not preventable. Since this surveillance was undertaken, the UK 
national guidelines have been updated again (in 2017) and premature labour 
added as an additional risk factor for the receipt of IAP.28 This could 
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potentially add up to 12% more cases to the proportion who might be offered 
IAP.  
 
Most countries with IAP guidelines to prevent EO GBS disease do so based 
on culture-based screening at 35-37 weeks gestation.29 The USA experience 
provides most support for this approach with notable reductions in EO disease 
from 1·7 per 1000 live-births in the 1990s to 0·21 per 1000 live-births in 
2015.30 A smaller number of countries have maintained risk-based guidelines, 
with reductions in EOD also noted in some (New Zealand 8 and Denmark 31), 
but not in all countries. Most recently, an increasing incidence of EO GBS 
disease has been described in the Netherlands (from 0·11 to 0·19 per 1000 
live births between 1987 and 2011), another country with risk-based 
prevention guidelines.32  
 
For both the UK and the Netherlands, this increase in incidence may reflect 
natural secular trends; for example, the serotypes responsible for both EOD 
and LOD disease have changed over time in both countries. A particular 
concern in this regard is the large number of isolates identified as ST17, a 
clone known to be particularly associated with a high risk of invasive neonatal 
disease and with meningitis.33,34  We do not have MLST data from the 
previous UK national surveillance study with which to compare; however, 
there has been an increase in the proportion of cases caused by serotype III 
between the two surveillance studies and many of these will belong to ST17.  
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Limitations.  
As with any surveillance, our estimates of disease burden should be 
considered a minimum incidence. Although we attempted to maximize our 
ascertainment using multiple sources, we recognise that there will inevitably 
be underreporting of cases. It is also important to emphasize that we have 
only reported the burden of culture-confirmed cases. Infants with probable 
(culture-negative) invasive GBS, stillbirths and early pregnancy losses due to 
maternal GBS, and the potential contribution of GBS to premature births, 
should all be considered when assessing the burden of this disease. 39 
We recognise that, in 53% of cases, isolates were not submitted to their 
respective reference laboratories for analysis and, therefore, the 
microbiological data are not complete. We note that isolates from cases of 
meningitis were more likely to have been submitted for confirmation and 
characterisation could impact the serotype and sequence type profiles that we 
have reported.  
 
An additional limitation is that the comprehensive surveillance studies were 
performed at two fixed 13-month time points (2000-1 and 2014-15) and not as 
part of a continuous surveillance over this 15 year interval. However, national 
passive surveillance for England and Wales is continuous and has shown that 
rates of disease have been consistent and slowly risen over the period 2000-
2010, in keeping with our findings.40 
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Finally, although invasive GBS disease became notifiable in ROI and NI since 
the previous surveillance, this is likely to have had only a minimal effect on 
overall estimates because the proportion of cases notified by non-clinical 
sources in ROI and NI was similar to that of the other countries. We also 
cannot comment on the impact of the risk-based IAP recommendations 
because we do not have information on total deliveries with risk factors who 
did and did not receive IAP. Clinical and/or microbiological changes in 
culturing practices may also have changed during the two surveillance 
periods, but we do not have any evidence to support or refute this.  
 
In conclusion the data from our study, particularly in relation to the increased 
incidence of invasive GBS disease in 2014-15 compared with 2000-01, 
together with a rising background incidence ascertained through passive 
surveillance, and despite the presence of national guidelines for EOD 
prevention, provide a strong rationale for an effective antenatal GBS vaccine. 
This is particularly so when considering prevention of LOD because, 
regardless of the strategy used to identify infants at high risk of EOD, IAP will 
have no impact on LOD. The leading candidates are capsular polysaccharide-
protein conjugate vaccines and our data suggest that a pentavalent conjugate 
vaccine (containing serotypes Ia, Ib, II, III, V) could cover around 94% of 
disease-causing isolates in young infants. 12 
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